These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30022224)

  • 1. A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors.
    Malik L; Zwiebel A; Cooper J
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):533-539. PubMed ID: 30022224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
    Shibata SI; Doroshow JH; Frankel P; Synold TW; Yen Y; Gandara DR; Lenz HJ; Chow WA; Leong LA; Lim D; Margolin KA; Morgan RJ; Somlo G; Newman EM
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1149-55. PubMed ID: 19322566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
    Chow LQ; Eckhardt SG; O'Bryant CL; Schultz MK; Morrow M; Grolnic S; Basche M; Gore L
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):631-46. PubMed ID: 18058098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
    Mortazavi A; Ling Y; Martin LK; Wei L; Phelps MA; Liu Z; Harper EJ; Ivy SP; Wu X; Zhou BS; Liu X; Deam D; Monk JP; Hicks WJ; Yen Y; Otterson GA; Grever MR; Bekaii-Saab T
    Invest New Drugs; 2013 Jun; 31(3):685-95. PubMed ID: 22847785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.
    Salazar R; Morales S; Gil-Martín M; Aguirre E; Oaknin A; Garcia M; Callies S; Wickremsinhe ER; Benhadji KA; Llombart A
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1205-15. PubMed ID: 24744161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
    Cleary JM; Lima CM; Hurwitz HI; Montero AJ; Franklin C; Yang J; Graham A; Busman T; Mabry M; Holen K; Shapiro GI; Uronis H
    Invest New Drugs; 2014 Oct; 32(5):937-45. PubMed ID: 24916770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
    Bhargava P; Marshall JL; Fried K; Williams M; Lefebvre P; Dahut W; Hanfelt J; Gehan E; Figuera M; Hawkins MJ; Rizvi NA
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):95-103. PubMed ID: 11561784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors.
    Saif MW; Sellers S; Li M; Wang W; Cusimano L; Wang H; Zhang R
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):871-82. PubMed ID: 17345085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
    Mavroudis D; Pappas P; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Nikolaidou M; Samonis G; Marselos M; Georgoulias V
    Ann Oncol; 2003 Feb; 14(2):304-12. PubMed ID: 12562660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.
    Desai AA; Schilsky RL; Young A; Janisch L; Stadler WM; Vogelzang NJ; Cadden S; Wright JA; Ratain MJ
    Ann Oncol; 2005 Jun; 16(6):958-65. PubMed ID: 15824081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
    Italiano A; Infante JR; Shapiro GI; Moore KN; LoRusso PM; Hamilton E; Cousin S; Toulmonde M; Postel-Vinay S; Tolaney S; Blackwood EM; Mahrus S; Peale FV; Lu X; Moein A; Epler J; DuPree K; Tagen M; Murray ER; Schutzman JL; Lauchle JO; Hollebecque A; Soria JC
    Ann Oncol; 2018 May; 29(5):1304-1311. PubMed ID: 29788155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).
    Richter S; Bedard PL; Chen EX; Clarke BA; Tran B; Hotte SJ; Stathis A; Hirte HW; Razak AR; Reedijk M; Chen Z; Cohen B; Zhang WJ; Wang L; Ivy SP; Moore MJ; Oza AM; Siu LL; McWhirter E
    Invest New Drugs; 2014 Apr; 32(2):243-9. PubMed ID: 23645447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.
    Michaelson MD; Zhu AX; Ryan DP; McDermott DF; Shapiro GI; Tye L; Chen I; Stephenson P; Patyna S; Ruiz-Garcia A; Schwarzberg AB
    Br J Cancer; 2013 Apr; 108(7):1393-401. PubMed ID: 23511559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.
    Galatin PS; Advani RH; Fisher GA; Francisco B; Julian T; Losa R; Sierra MI; Sikic BI
    Invest New Drugs; 2011 Oct; 29(5):971-7. PubMed ID: 20349264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of rubitecan and gemcitabine in patients with advanced malignancies.
    Fracasso PM; Rader JS; Govindan R; Herzog TJ; Arquette MA; Denes A; Mutch DG; Picus J; Tan BR; Fears CL; Goodner SA; Sun SL
    Ann Oncol; 2002 Nov; 13(11):1819-25. PubMed ID: 12419757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
    Patnaik A; Rowinsky EK; Tammara BK; Hidalgo M; Drengler RL; Garner AM; Siu LL; Hammond LA; Felton SA; Mallikaarjun S; Von Hoff DD; Eckhardt SG
    J Clin Oncol; 2000 Dec; 18(23):3974-85. PubMed ID: 11099327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis.
    Doi T; Hamaguchi T; Shitara K; Iwasa S; Shimada Y; Harada M; Naito K; Hayashi N; Masada A; Ohtsu A
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):569-578. PubMed ID: 28224231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies.
    Fountzilas C; Javle M; Tan W; Ma Y; Fetterly G; Iyer R; Johnson C
    Cancer; 2018 Oct; 124(19):3890-3899. PubMed ID: 30299542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors.
    Paz-Ares L; Forster M; Boni V; Szyldergemajn S; Corral J; Turnbull S; Cubillo A; Teruel CF; Calderero IL; Siguero M; Bohan P; Calvo E
    Invest New Drugs; 2017 Apr; 35(2):198-206. PubMed ID: 27873130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.